Ambulatory blood pressure monitorisation in children with recombinant growth hormone treatment

Emel Hatun Aytaç Kaplan; Zümrüt Kocabey Sütçü; Eren Soyaltın; Hasan Onal

doi:10.1515/jpem-2023-0396

Article

Ambulatory blood pressure monitorisation in children with recombinant growth hormone treatment

Emel Hatun Aytaç Kaplan , Zümrüt Kocabey Sütçü , Eren Soyaltın and Hasan Onal

Published/Copyright: November 28, 2023

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Pediatric Endocrinology and Metabolism Volume 37 Issue 1

Abstract

Objectives

It is safe to use recombinant growth hormone in children. Studies have shown it to be effective and safe, except for a few side effects in the short and long term after treatment. The present study investigated the presence of hypertension in pediatric patients receiving growth hormone treatment using 24 h ambulatory blood pressure monitoring (ABPM).

Methods

This study is a single-center, retrospective study. Eighty-four patients aged 5–16 years who received growth hormone treatment for at least 3 months, who underwent 24 h ABPM were analyzed. They were compared with 67 patients who had no risk factors for hypertension.

Results

In the study, 84 rhGH-treated patients (45.2 % male, 54.8 % female) and 67 healthy control groups (49.3 % male, 50.7 % female) were analyzed. The mean age of the patient group was 10.83±2.85 years and the mean age of the healthy control group was 13.1±2.93 years. The diagnostic classification of the patients receiving treatment was as follows: 66.6 % (n=56) partial growth hormone deficiency, 22.6 % (n=19) growth hormone deficiency, 7.1 % (n=6) bioactive growth hormone, 2.3 % (n=2) idiopathic short stature, 1.1 % (n=1) low birth weight for gestational age (SGA). Body mass index was significantly lower in the treated group (p=0.013). The duration of treatment was 6.04±4.9 months. Daytime diastolic blood pressure was significantly lower in the treated group (p=0.001). There was no correlation between BMI and ABPM parameters in the treatment group and the control group.

Conclusions

The present study shows that growth hormone treatment is safe in terms of high blood pressure.

Keywords: ambulatory blood pressure monitoring (ABPM); children; growth hormone

Corresponding author: Emel Hatun Aytaç Kaplan, Pediatric Endocrinology, Başakşehir Çam ve Sakura City Hospital, İstanbul 34000, Türkiye, E-mail: emel_ctf@hotmail.com

Research ethics: Approval was obtained from the Ethics Committee of the hospital (Başakşehir Çam ve Sakura City Hospital) (protocol code: 2022-372).
Informed consent: Informed consent was obtained from all individuals included in this study.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Research funding: None declared.
Data availability: Not applicable.

References

1. Raben, MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901–3. https://doi.org/10.1210/jcem-18-8-901.Search in Google Scholar PubMed

2. Yuen, KCJ, Biller, BMK, Radovick, S, Carmichael, JD, Jasim, S, Pantalone, KM, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract 2019;25:1191–232. https://doi.org/10.4158/gl-2019-0405.Search in Google Scholar

3. Child, CJ, Zimmermann, AG, Chrousos, GP, Cummings, E, Deal, CL, Hasegawa, T, et al.. Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational programe. J Clin Endocrinol Metab 2019;104:379–89. https://doi.org/10.1210/jc.2018-01189.Search in Google Scholar PubMed PubMed Central

4. Bell, J, Parker, KL, Swinford, RD, Hoffman, AR, Maneatis, T, Lippe, B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010;95:167–77. https://doi.org/10.1210/jc.2009-0178.Search in Google Scholar PubMed

5. Poidvin, A, Weill, A, Ecosse, E, Coste, J, Carel, JC. Risk of diabetes treated in early adulthood after growth hormone treatment of short stature in childhood. J Clin Endocrinol Metab 2017;102:1291–8. https://doi.org/10.1210/jc.2016-3145.Search in Google Scholar PubMed

6. Swerdlow, AJ, Cooke, R, Albertsson-Wikland, K, Borgström, B, Butler, G, Cianfarani, S, et al.. Description of the SAGhE cohort: a large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr 2015;84:172–83. https://doi.org/10.1159/000435856.Search in Google Scholar PubMed PubMed Central

7. Sävendahl, L, Cooke, R, Tidblad, A, Beckers, D, Butler, G, Cianfarani, S, et al.. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet Diabetes Endocrinol 2020;8:683–92. https://doi.org/10.1016/s2213-8587(20)30163-7.Search in Google Scholar PubMed

8. Flynn, TJ, Kaelber, DC, Baker-Smith, CM, Blowey, D, Carroll, AE, Daniels, SR, et al.. Clinical Practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017;140. https://doi.org/10.1542/peds.2017-1904.Search in Google Scholar PubMed

9. Chesover, AD, Dattani, MT. Evaluation of growth hormone stimulation testing in children. Clin Endocrinol 2016;84:708–14. https://doi.org/10.1111/cen.13035.Search in Google Scholar PubMed

10. Ranke, MB. Growth hormone deficiency: diagnostic principles and practice: diagnostic of endocrine function in children and adolescents, 4th ed. Basel: Karger; 2011:101–37 pp.10.1159/000327405Search in Google Scholar

11. Demir, K, Konakçı, E, Özkaya, G, Kasap Demir, B, Özen, S, Aydın, M, et al.. New features for childmetrics: further growth references and blood pressure calculations. J Clin Res Pediatr Endocrinol 2020;12:125–9. https://doi.org/10.4274/jcrpe.galenos.2019.2019.0127.Search in Google Scholar PubMed PubMed Central

12. Neyzi, O, Bundak, R, Gökçay, G, Günöz, H, Furman, A, Darendeliler, F, et al.. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 2015;7:280–93. https://doi.org/10.4274/jcrpe.2183.Search in Google Scholar PubMed PubMed Central

13. Franssen, PM, Imholz, BP. Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria. Blood Press Monit 2010;15:229–31. https://doi.org/10.1097/mbp.0b013e328339be38.Search in Google Scholar PubMed

14. Wühl, E, Witte, K, Soergel, M, Mehls, O, Schaefer, F, German Working Group on Pediatric Hypertension. Distribution of 24 h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 2002;20:1995–2007. https://doi.org/10.1097/00004872-200210000-00019.Search in Google Scholar PubMed

15. Alberti, KG, Zimmet, P, Shaw, J. Metabolic syndrome–a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med2006;23:469–80. https://doi.org/10.1111/j.1464-5491.2006.01858.x.Search in Google Scholar PubMed

16. De Leonibus, C, De Marco, S, Stevens, A, Clayton, P, Chiarelli, F, Mohn, A. Growth hormone deficiency in prepubertal children: Predictive markers of cardiovascular disease. Hormone Res Paediatr 2016;85:363–71. https://doi.org/10.1159/000444143.Search in Google Scholar PubMed

17. Li, Y, Zhang, Y, Zhang, M, Yang, W, Ji, B, Pan, H, et al.. Growth hormone peak modifies the effect of BMI on increased systolic blood pressure in children with short stature. Sci Rep 2019;9:7879. https://doi.org/10.1038/s41598-019-44299-9.Search in Google Scholar PubMed PubMed Central

18. Karlberg, BE, Ottosson, AM. Acromegaly and hypertension: role of the renin–angiotensin–aldosterone system. Acta Endocrinol 1982;100:581–7. https://doi.org/10.1530/acta.0.1000581.Search in Google Scholar PubMed

19. Barton, JS, Preece, MA, Çayı, CG, Brook, CGD. Blood pressure and the renin–angiotensin–aldosterone system in children receiving recombinant human growth hormone. Clin Endocrinol 1993;38:245–51. https://doi.org/10.1111/j.1365-2265.1993.tb01002.x.Search in Google Scholar PubMed

20. Zhang, S, Li, Z, Lv, Y, Sun, L, Xiao, X, Gang, X, et al.. Cardiovascular effects of growth hormone (GH) treatment on GH-deficient adults: a meta-analysis update. Pituitary 2020;23:467–75. https://doi.org/10.1007/s11102-020-01036-0.Search in Google Scholar PubMed

21. Hoffman, DM, Crampton, L, Sernia, C, Nguyen, TV, Ho, KK. Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab 1996;81:1123–8. https://doi.org/10.1210/jc.81.3.1123.Search in Google Scholar

22. Gill, D. Effect of growth hormone on short normal children. Br Med J (Clin Res Ed). 1987;295:1063. https://doi.org/10.1136/bmj.295.6605.1063-a.Search in Google Scholar

23. Martins, VJB, Sesso, R, Clemente, APG, Fernandes, MBF, Sawaya, AL. Albuminuria, renal function and blood pressure in undernourished children and recovered from undernutrition. Pediatr Nephrol 2017;32:1555–63. https://doi.org/10.1007/s00467-017-3602-y.Search in Google Scholar PubMed

24. Wu, O, Leng, JH, Yang, FF, Yang, HM, Zhang, H, Li, ZF, et al.. A comparative research on obesity hypertension by the comparisons and associations between waist circumference, body mass index with systolic and diastolic blood pressure, and the clinical laboratory data between four special Chinese adult groups. Clin Exp Hypertens 2018;40:16–21. https://doi.org/10.1080/10641963.2017.1281940.Search in Google Scholar PubMed

25. Afolabi, IS, Chinedu, SN, Iweala, EJ, Ogunlana, OO, Azuh, DE. Body mass index and blood pressure in a semi-urban community in Ota, Nigeria. Food Publ Health 2015;5:157–63.Search in Google Scholar

Received: 2023-09-02

Accepted: 2023-11-13

Published Online: 2023-11-28

Published in Print: 2024-01-29

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jpem-2023-0396

Keywords for this article

ambulatory blood pressure monitoring (ABPM); children; growth hormone